An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

NCT00489385 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
HCV

Interventions

DRUG: Albinterferon
DRUG: Ribavirin
DRUG: Albuferon

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)